Everyone’s calling this a cardiology story. I think it’s a radiology story.
The FDA just cleared Elucid’s FFR-IQ software, an AI-powered tool that estimates fractional flow reserve directly from coronary CT angiography scans. No catheterization required. According to Diagnostic Imaging, a recent study of FFR-IQ showed 92.2 percent sensitivity and 93.1 percent specificity for non-invasive FFR estimation from CCTA images.
Those numbers matter. But what matters more is what they represent.
For decades, the gold standard for assessing whether a coronary lesion is functionally significant has been invasive FFR, a wire-based pressure measurement done during catheterization. That procedure carries real procedural risk, real cost, and real patient burden. This clearance says: a CT scan and an algorithm can now do a version of that work.
The underlying technology is called BioIntegrated FFR-CT. What sets it apart from earlier FFR-CT approaches is what it incorporates into the estimate. Most models focus on coronary anatomy and flow. Elucid’s approach adds plaque composition to that picture, combining anatomy, physiology, and plaque characteristics into a single integrated assessment.
As Amir Ahmadi, MD, lead scientific advisor for Elucid and clinical associate professor at the Icahn School of Medicine at Mount Sinai, put it: “Plaque composition, coronary anatomy, and physiology are closely connected.”
That integration is the actual leap.
🔹 Anatomy alone tells you the shape of the lesion.
🔹 Physiology tells you if it restricts flow.
🔹 Plaque composition tells you how dangerous it actually is.
Combining all three non-invasively, from a scan the patient already had, is a different category of decision support.
Where I sit in lung cancer screening AI, we talk constantly about what it means to extract more clinical signal from imaging that already exists. LDCT gives us lung nodules, yes. But it also surfaces cardiovascular findings, bone density, muscle mass. The scan sees more than the indication asks for.
FFR-IQ is the cardiac equivalent of that logic. The CT was already ordered. The AI now extracts a layer of functional information that previously required a separate invasive procedure to obtain.
The practical implication, according to Elucid, is that FFR-IQ may help reduce unnecessary catheterization by identifying which patients are better suited for revascularization and which patients may benefit from medical or preventive treatment instead.
That is a meaningful clinical fork in the road.
We are at an inflection point where the value of an imaging scan is no longer fixed at the time of acquisition. AI is expanding what a single scan can tell us, and FFR-IQ is one of the cleaner examples of that trend becoming real clinical infrastructure.
The question worth sitting with: as AI turns existing scans into multi-signal diagnostic tools, how does reimbursement and workflow keep up? The clearance exists. The payment pathway and care coordination often do not.
👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on LinkedIn: https://www.linkedin.com/newsletters/the-oatmeal-bite-7368331304385314817/
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
